IRIS Accounts Production v25.1.4.42 09301565 Board of Directors 1.12.23 30.11.24 30.11.24 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh093015652023-11-30093015652024-11-30093015652023-12-012024-11-30093015652022-11-30093015652022-12-012023-11-30093015652023-11-3009301565ns15:EnglandWales2023-12-012024-11-3009301565ns14:PoundSterling2023-12-012024-11-3009301565ns10:Director12023-12-012024-11-3009301565ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3009301565ns10:SmallEntities2023-12-012024-11-3009301565ns10:AuditExempt-NoAccountantsReport2023-12-012024-11-3009301565ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3009301565ns10:FullAccounts2023-12-012024-11-3009301565ns10:Director22023-12-012024-11-3009301565ns10:CompanySecretary12023-12-012024-11-3009301565ns10:RegisteredOffice2023-12-012024-11-3009301565ns5:CurrentFinancialInstruments2024-11-3009301565ns5:CurrentFinancialInstruments2023-11-3009301565ns5:ShareCapital2024-11-3009301565ns5:ShareCapital2023-11-3009301565ns5:RevaluationReserve2024-11-3009301565ns5:RevaluationReserve2023-11-3009301565ns5:PlantMachinery2023-12-012024-11-3009301565ns5:FurnitureFittings2023-12-012024-11-3009301565ns5:MotorVehicles2023-12-012024-11-3009301565ns5:LandBuildings2023-11-3009301565ns5:PlantMachinery2023-11-3009301565ns5:LandBuildings2023-12-012024-11-3009301565ns5:LandBuildings2024-11-3009301565ns5:PlantMachinery2024-11-3009301565ns5:LandBuildings2023-11-3009301565ns5:PlantMachinery2023-11-3009301565ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3009301565ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-3009301565ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-11-3009301565ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2023-11-30
REGISTERED NUMBER: 09301565 (England and Wales)














KANDALL MEDICAL LIMITED

Unaudited Financial Statements

for the Year Ended 30 November 2024






KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Contents of the Financial Statements
for the Year Ended 30 November 2024










Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 7


KANDALL MEDICAL LIMITED

Company Information
for the Year Ended 30 November 2024







Directors: Dr G Alluvada
Dr P Kandi





Secretary: Dr P Kandi





Registered office: Artisans' House
7 Queensbridge
Northampton
Northamptonshire
NN4 7BF





Registered number: 09301565 (England and Wales)





Accountants: Cobley Desborough
Chartered Certified Accountants
Chartered Tax Advisers
Artisans' House
7 Queensbridge
Northampton
Northamptonshire
NN4 7BF

KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Balance Sheet
30 November 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 16,356 74,075
Investment property 5 60,000 -
76,356 74,075

CURRENT ASSETS
Debtors 6 69,869 -
Cash at bank 16,482 58,950
86,351 58,950
CREDITORS
Amounts falling due within one year 7 30,219 14,311
NET CURRENT ASSETS 56,132 44,639
TOTAL ASSETS LESS CURRENT
LIABILITIES

132,488

118,714

PROVISIONS FOR LIABILITIES 4,207 3,185
NET ASSETS 128,281 115,529

CAPITAL AND RESERVES
Called up share capital 100 100
Revaluation reserve 4,685 -
Retained earnings 123,496 115,429
SHAREHOLDERS' FUNDS 128,281 115,529

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Balance Sheet - continued
30 November 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 6 June 2025 and were signed on its behalf by:





Dr G Alluvada - Director


KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Notes to the Financial Statements
for the Year Ended 30 November 2024


1. STATUTORY INFORMATION

Kandall Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 20% on reducing balance
Motor vehicles - 25% on reducing balance

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Debtors and creditors receivable / payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Going concern
The current economic conditions present increased risks for all businesses. In response to such conditions, the director has carefully considered these risks, including an assessment of uncertainty on future trading projections for a period of at least twelve months from the date of signing the financial statements, and the extent to which they might affect the preparation of the financial statements on a going concern basis.

Based on this assessment, the director considers that the Company maintains an appropriate level of liquidity, sufficient to meet the demands of the business including any capital and servicing obligations of external liabilities.

In addition, the Company's assets are assessed for recoverability on a regular basis, and the director considers that the Company is not exposed to losses of these assets which would affect their decision to adopt the going concern basis.

The director is therefore satisfied and has a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and that there are no material uncertainties that lead to significant doubt upon the Company's ability to continue as a going concern. Theses financial statements have therefore been prepared on a going concern basis.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2023 - 3 ) .

KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024


4. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
Cost
At 1 December 2023 54,216 51,880 106,096
Additions - 1,910 1,910
Disposals - (1,984 ) (1,984 )
Reclassification/transfer (54,216 ) - (54,216 )
At 30 November 2024 - 51,806 51,806
Depreciation
At 1 December 2023 - 32,021 32,021
Charge for year - 4,944 4,944
Eliminated on disposal - (1,515 ) (1,515 )
At 30 November 2024 - 35,450 35,450
Net book value
At 30 November 2024 - 16,356 16,356
At 30 November 2023 54,216 19,859 74,075

5. INVESTMENT PROPERTY
Total
£   
Fair value
Revaluations 5,784
Reclassification/transfer 54,216
At 30 November 2024 60,000
Net book value
At 30 November 2024 60,000

Fair value at 30 November 2024 is represented by:
£   
Valuation in 2024 5,784
Cost 54,216
60,000

KANDALL MEDICAL LIMITED (REGISTERED NUMBER: 09301565)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024


6. DEBTORS
2024 2023
£    £   
Amounts falling due within one year:
Trade debtors 3,640 -

Amounts falling due after more than one year:
Other debtors 66,229 -

Aggregate amounts 69,869 -

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 612 -
Taxation and social security 3,113 1,695
Other creditors 26,494 12,616
30,219 14,311